carbonic acid 4-nitro-phenyl ester 2-[2-(2-propoxy-ethoxy)-ethoxy]-ethyl ester | 874208-95-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: carbonic acid 4-nitro-phenyl ester 2-[2-(2-propoxy-ethoxy)-ethoxy]-ethyl ester
• 英文别名: (4-Nitrophenyl) 2-[2-(2-propoxyethoxy)ethoxy]ethyl carbonate
• CAS: 874208-95-4
• 化学式: C₁₆H₂₃NO₈
• 分子量: 357.361
• InChiKey: AISQZSIFGXQMAC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  25
• 可旋转键数：
  14
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  109
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  2-[2-(2-丙氧基乙氧基)乙氧基]乙醇 、 对硝基苯基氯甲酸酯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 以63%的产率得到carbonic acid 4-nitro-phenyl ester 2-[2-(2-propoxy-ethoxy)-ethoxy]-ethyl ester
  参考文献：
  名称：

  Fatty acid formulations for oral delivery of proteins and peptides, and uses thereof

  摘要：

  脂肪酸组成物用于制备药物，例如蛋白质和肽，蛋白质和肽共轭物以及/或阳离子-多肽共轭物复合物的给药。特别地，本发明提供了一种固体制剂，用于经口摄入口服，其含有约0.1至约75％w/w的脂肪酸成分，其中所述脂肪酸成分包括饱和或不饱和的C4，C5，C6，C7，C8，C9，C10，C11或C12脂肪酸和/或这些脂肪酸的盐；以及治疗剂。此外，本发明提供了一种液体制剂，用于经口摄入口服，包括：约0.1至约10％w/v的脂肪酸成分，其中所述脂肪酸成分包括饱和或不饱和的C4，C5，C6，C7，C8，C9，C10，C11或C12脂肪酸和/或这些脂肪酸的盐；以及治疗剂。

  公开号：

  US20060018874A1

文献信息

• Cation complexes of insulin compound conjugates, formulations and uses thereof
  申请人：Radhakrishnan Balasingam

  公开号：US20060019873A1

  公开（公告）日：2006-01-26

  An insulin compound coupled to a modifying moiety having a formula: —X—R 1 —Y-PAG-Z-R  (Formula VI) where, X, Y and Z are independently selected linking groups and each is optionally present, and X, when present, is coupled to the insulin compound by a covalent bond, either R 1 or R 2 is is a lower alkyl, optionally including a carbonyl group, and when R 1 is a lower alkyl, R 2 is a capping group, and PAG is a linear or branched carbon chain incorporating one or more alkalene glycol moieties, and optionally incorporating one or more additional moieties selected from the group consisting of —S—, —O—, —N—, and —C(O)—, and where the modifying moiety has a maximum number of 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 heavy atoms.

  一种胰岛素化合物，与具有以下式的修饰基偶联：—X—R1—Y-PAG-Z-R（VI式）其中，X、Y和Z是独立选择的连接基，每个都可以选择存在，且当X存在时，它通过共价键与胰岛素化合物偶联，R1或R2是较低的烷基，可以包括一个羰基基团，当R1是较低的烷基时，R2是一个端基，PAG是一种线性或支链碳链，包括一个或多个碱基二醇基团，并且可以包括从以下组中选择的一个或多个附加基团：—S—、—O—、—N—和—C（O）—，其中修饰基最多有3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23、24或25个重原子。
• Cation complexes of insulin compund conjugates, formulation and uses thereof
  申请人：Radhakrishnan Balasingam

  公开号：US20060019874A1

  公开（公告）日：2006-01-26

  The invention provides a complex including a cation and an insulin compound conjugate. The insulin compound conjugate includes insulin compound, such as human insulin or an analog thereof, conjugated to a modifying moiety, such as a polyethylene glycol moiety. The invention also includes solids and pharmaceutical compositions including such complexes, methods of making such complexes, and methods of using such complexes in the treatment of insulin compound deficiencies and other ailments. Further, the invention includes novel insulin compound conjugates and modifying moieties for use in making novel insulin compound conjugates. The invention also includes fatty acid compositions for administration of pharmaceutical agents, such as the novel insulin compound conjugates, and/or the cation-insulin compound conjugate complexes of the invention.

  本发明提供了一种包括阳离子和胰岛素化合物共轭物的复合物。胰岛素化合物共轭物包括胰岛素化合物，如人类胰岛素或其类似物，与修饰基团，如聚乙二醇基团结合。本发明还包括包括这种复合物的固体和制药组合物，制备这种复合物的方法以及使用这种复合物治疗胰岛素化合物缺乏和其他疾病的方法。此外，本发明还包括用于制备新型胰岛素化合物共轭物的新型胰岛素化合物共轭物和修饰基团。本发明还包括用于给药的脂肪酸组合物，例如用于给药本发明的新型胰岛素化合物共轭物和/或阳离子-胰岛素化合物共轭物复合物的制药剂。
• FATTY ACID FORMULATIONS AND ORAL DELIVERY OF PROTEINS AND PEPTIDES, AND USES THEREOF
  申请人：Radhakrishnan Balasingam

  公开号：US20100105605A1

  公开（公告）日：2010-04-29

  Fatty acid compositions for administration of of pharmaceutical agents, such as proteins and peptides, protein and peptide conjugates, and/or cation-polypeptide conjugate complexes. In particular, the invention provides a solid pharmaceutical composition formulated for oral administration by ingestion, having from about 0.1 to about 75% w/w fatty acid component, where the fatty acid component comprises saturated or unsaturated C4, C5, C6, C7, C8, C9, C10, C11, or C12 fatty acids and/or salts of such fatty acids; and a therapeutic agent. Further, the invention provides a liquid pharmaceutical composition formulated for oral administration by ingestion, comprising: from about 0.1 to about 10% w/v fatty acid component, where the fatty acid component comprises saturated or unsaturated C4, C5, C6, C7, C8, C9, C10, C11, or C12 fatty acids and/or salts of such fatty acids; and a therapeutic agent.

  脂肪酸组成用于制备药物，例如蛋白质和肽，蛋白质和肽共轭物和/或阳离子-多肽共轭物复合物的给药。特别地，本发明提供一种固体制剂，用于口服给药，含有约0.1至约75% w/w的脂肪酸成分，其中脂肪酸成分包括饱和或不饱和的C4、C5、C6、C7、C8、C9、C10、C11或C12脂肪酸和/或这些脂肪酸的盐；以及治疗剂。此外，本发明提供一种液体制剂，用于口服给药，包括：约0.1至约10% w/v的脂肪酸成分，其中脂肪酸成分包括饱和或不饱和的C4、C5、C6、C7、C8、C9、C10、C11或C12脂肪酸和/或这些脂肪酸的盐；以及治疗剂。
• CATION COMPLEXES OF INSULIN COMPOUND CONJUGATES, FORMULATIONS AND USES THEREOF
  申请人：Radhakrishnan Balasingam

  公开号：US20110118179A1

  公开（公告）日：2011-05-19

  An insulin compound coupled to a modifying moiety having a formula: —X—R 1 —Y-PAG-Z—R 2 (Formula VI) where, X, Y and Z are independently selected linking groups and each is optionally present, and X, when present, is coupled to the insulin compound by a covalent bond, either R 1 or R 2 is is a lower alkyl, optionally including a carbonyl group, and when R 1 is a lower alkyl, R 2 is a capping group, and PAG is a linear or branched carbon chain incorporating one or more alkalene glycol moieties, and optionally incorporating one or more additional moieties selected from the group consisting of —S—, —O—, —N—, and —C(O)—.

  一种胰岛素化合物，与具有以下公式的修饰基团偶联：—X—R1—Y-PAG-Z—R2（公式VI）其中，X、Y和Z是独立选择的连接基团，每个基团都可以选择性地存在，并且当存在X时，它通过共价键与胰岛素化合物偶联，R1或R2是较低的烷基，可以包括一个羰基基团，当R1是较低的烷基时，R2是一个顶端基团，PAG是一个线性或支链碳链，包括一个或多个碱基乙二醇基团，并且可以选择性地包括从群组中选择的一个或多个附加基团，所述群组包括—S—，—O—，—N—和—C（O）—。
• INSULIN-OLIGOMER CONJUGATES, FORMULATIONS AND USES THEREOF
  申请人：Radhakrishnan Balasingam

  公开号：US20110124553A1

  公开（公告）日：2011-05-26

  An insulin compound coupled to a modifying moiety having a formula: —X—R 1 —Y—PAG-Z—R 2 (Formula VI) where, X, Y and Z are independently selected linking groups and each is optionally present, and X, when present, is coupled to the insulin compound by a covalent bond, either R 1 or R 2 is a lower alkyl, optionally including a carbonyl group, and when R 1 is a lower alkyl, R 2 is a capping group, and PAG is a linear or branched carbon chain incorporating one or more alkalene glycol moieties, and optionally incorporating one or more additional moieties selected from the group consisting of —S—, —O—, —N—, and —C(O)—.

  一种胰岛素化合物与修饰基团偶联，公式如下：—X—R1—Y—PAG-Z—R2（公式VI），其中，X、Y和Z是独立选择的连接基团，每个都可以选择性地存在，当X存在时，通过共价键与胰岛素化合物偶联，R1或R2是低碳链基团，可以包括一个羰基基团，当R1是低碳链基团时，R2是一个帽基团，PAG是一个线性或支链碳链，包含一个或多个碱性乙二醇基团，并可以选择性地包含一个或多个来自—S—、—O—、—N—和—C(O)—的附加基团。